BR112014000810A8 - Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos - Google Patents

Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos

Info

Publication number
BR112014000810A8
BR112014000810A8 BR112014000810A BR112014000810A BR112014000810A8 BR 112014000810 A8 BR112014000810 A8 BR 112014000810A8 BR 112014000810 A BR112014000810 A BR 112014000810A BR 112014000810 A BR112014000810 A BR 112014000810A BR 112014000810 A8 BR112014000810 A8 BR 112014000810A8
Authority
BR
Brazil
Prior art keywords
hypertension
inflammation
gamma
treatment
methods
Prior art date
Application number
BR112014000810A
Other languages
English (en)
Other versions
BR112014000810A2 (pt
Inventor
jackson roberts L
Amarnath Venkataraman
g harrison David
Kirabo Annet
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of BR112014000810A2 publication Critical patent/BR112014000810A2/pt
Publication of BR112014000810A8 publication Critical patent/BR112014000810A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

MÉTODOS PARA TRATAR A INFLAMAÇÃO E HIPERTENSÃO COM SKAVENGERS GAMMA - CETOALDEÍDO. Urn método de tra tarnento de, pelo menos, urn de inflamação, psoríase, e/ou hipertensão, compreendendo a administração a urn paciente em necessidade há de urna quantidade eficaz eliminadora de garna-cetoaldeído de urn composto de varrimento garna-cetoaldeído.
BR112014000810A 2011-07-12 2012-07-12 Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos BR112014000810A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Publications (2)

Publication Number Publication Date
BR112014000810A2 BR112014000810A2 (pt) 2017-06-13
BR112014000810A8 true BR112014000810A8 (pt) 2022-11-29

Family

ID=47506934

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000810A BR112014000810A8 (pt) 2011-07-12 2012-07-12 Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos

Country Status (11)

Country Link
US (2) US10975033B2 (pt)
EP (1) EP2731597B1 (pt)
JP (1) JP6280033B2 (pt)
KR (2) KR20140050661A (pt)
CN (2) CN111494352A (pt)
AU (1) AU2012281061B2 (pt)
BR (1) BR112014000810A8 (pt)
CA (1) CA2844150C (pt)
MX (1) MX2014000515A (pt)
PL (1) PL2731597T3 (pt)
WO (1) WO2013010034A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US10166248B1 (en) 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
WO2018009720A1 (en) * 2016-07-06 2018-01-11 Vanderbilt University Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan
AU2017324935B2 (en) * 2016-09-06 2021-10-21 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
AU2017362328B2 (en) * 2016-11-15 2022-03-31 Vanderbilt University Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
MX2019012659A (es) * 2017-04-27 2020-07-24 Univ Vanderbilt Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
CA3074736A1 (en) * 2017-09-05 2019-03-14 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) * 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) * 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
AU5659796A (en) 1995-05-19 1996-11-29 Kissei Pharmaceutical Co. Ltd. 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1341532B1 (en) * 2000-11-02 2006-07-26 University of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) * 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
US8410068B2 (en) * 2007-10-05 2013-04-02 Index Pharmaceuticals Ab Compounds for the treatment or alleviation of edema, and methods for their use
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Also Published As

Publication number Publication date
JP2014524918A (ja) 2014-09-25
US10975033B2 (en) 2021-04-13
KR20190069607A (ko) 2019-06-19
JP6280033B2 (ja) 2018-02-14
AU2012281061A1 (en) 2014-02-20
WO2013010034A2 (en) 2013-01-17
EP2731597C0 (en) 2023-12-20
EP2731597A4 (en) 2015-04-08
EP2731597B1 (en) 2023-12-20
CA2844150C (en) 2019-09-03
MX2014000515A (es) 2014-03-27
AU2012281061B2 (en) 2017-08-03
WO2013010034A3 (en) 2013-03-28
CN103796648A (zh) 2014-05-14
CN111494352A (zh) 2020-08-07
EP2731597A2 (en) 2014-05-21
US20210261508A1 (en) 2021-08-26
BR112014000810A2 (pt) 2017-06-13
CA2844150A1 (en) 2013-01-17
CN103796648B (zh) 2019-10-25
KR102050700B1 (ko) 2019-11-29
KR20140050661A (ko) 2014-04-29
US20140256774A1 (en) 2014-09-11
PL2731597T3 (pl) 2024-04-29

Similar Documents

Publication Publication Date Title
BR112014000810A8 (pt) Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
EA201290919A1 (ru) Индазольные соединения и их применение
EA201491221A1 (ru) Новые молекулы, ингибирующие jnk, для лечения различных болезней
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
IN2015DN00450A (pt)
MX2013003638A (es) Tratamiento en combinacion para rosacea.
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201591843A1 (ru) Способы лечения несовершенного остеогенеза
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]